Sibu-Med, Sibutramine, 20 mg, 60 Tabs

Sibutramine Hydrochloride 20 mg by Bioniche Pharma is an orally bioavailable, centrally active therapeutic agent engineered for the management of exogenous obesity. Formulated by Bioniche Pharma to modulate neurotransmitter reuptake pathways, Bioniche Pharma Sibutramine Hydrochloride promotes early post-prandial satiety and supports resting metabolic rate maintenance.

PHYSICOCHEMICAL CHARACTERISTICS

Sibutramine Hydrochloride Monohydrate in Bioniche Pharma Sibutramine Hydrochloride exists as a white to off-white crystalline substance. It exhibits an aqueous solubility profile of 2.9 mg/mL in a pH 5.2 buffered environment and has an octanol:water partition coefficient of 30.9 at pH 5.0, reflecting its marked lipophilicity and efficient cellular membrane absorption.

CLINICAL PHARMACOLOGY & DYNAMICS

Distinct from classic amphetamine-derived anorectics, Bioniche Pharma Sibutramine Hydrochloride acts through its active secondary and primary amine metabolites to selectively block the presynaptic reuptake of norepinephrine, serotonin ($5\text{-HT}$), and to a minor degree, dopamine. This pharmacological activity amplifies satiety signals (reducing total caloric consumption) while countering the compensatory drop in resting energy expenditure that normally accompanies dietary restriction.

INDICATIONS & CLINICAL USE

• Medical management of exogenous obesity in patients with an elevated Body Mass Index (BMI), encompassing structured weight reduction and weight maintenance protocols using Bioniche Pharma Sibutramine Hydrochloride.
• Adjunctive therapeutic intervention integrated alongside a medically supervised, energy-restricted diet and behavioral modification plan using Bioniche Pharma formulations.

DOSAGE & ADMINISTRATION

Dosing protocols for Sibutramine Hydrochloride by Bioniche Pharma must be individually calculated and maintained under direct medical oversight. Thorough evaluation of baseline cardiovascular parameters, patient eligibility, and ongoing blood pressure screening is required prior to and during Bioniche Pharma therapy.

ADVERSE REACTIONS & CLINICAL MONITORING

Adverse effects associated with Bioniche Pharma Sibutramine Hydrochloride stem primarily from central monoaminergic reuptake inhibition and peripheral sympathomimetic stimulation:

• Common Reactions: Xerostomia (dry mouth), appetite suppression, sleep disturbances (insomnia), constipation, and headaches (cephalea) reported during Bioniche Pharma Sibutramine Hydrochloride administration.
• Cardiovascular Considerations: Sympathomimetic activity can cause dose-dependent elevations in resting pulse rate and systemic blood pressure; routine clinical monitoring of circulatory parameters is essential throughout Bioniche Pharma treatment.

STORAGE & HANDLING

Store Bioniche Pharma Sibutramine Hydrochloride in a dry, cool environment protected from direct sunlight, excessive heat, and moisture. Store securely out of the reach and sight of children.